TFF Pharma, Augmenta Bioworks Select Lead Antibody Program To Develop For COVID-19

by Vandana Singh, Benzinga Editor

June 22, 2021 10:59 AM | 1 min read

Augmenta Bioworks and TFF Pharmaceuticals Inc TFFP have selected AUG-3387 as the first lead monoclonal antibody for clinical development against COVID-19 under their joint development Collaboration Agreement.
AUG-3387 will be developed as an inhaled therapy for the treatment of COVID-19 disease.
Notably, in in vitro preclinical testing, AUG-3387 effectively neutralizes SARS-CoV2 and has demonstrated activity against all variant strains tested to date.
TFF and Augmenta have an ongoing commitment to monitor the activity of AUG-3387 against emerging variants and will be completing in vivo preclinical efficacy studies in the coming weeks.
Price Action: TFFP shares are down 2.98% at $10.09 during the market trading session on the last check Tuesday.

Posted In: Biotech News Health Care General Briefs Covid-19

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.